RecruitingPhase 3NCT03955445
10
studies recruiting now
as of 7 Sept 2026
33
studies registered in total
as of 7 Sept 2026
29
countries with a recruiting site
as of 7 Sept 2026
5 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 4NCT07746895
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
RecruitingPhase 2NCT06419205
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
RecruitingPhase 1NCT07483827
A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy
RecruitingPhase 3NCT04817618
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 10 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new C3 glomerulopathy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About C3 glomerulopathy
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment and 2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Pegcetacoplan (Aspaveli)
Phase 3Iptacopan
Phase 1/2Ruxoprubart
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).